Correction

The article ‘Reducing cardiovascular risk in people with chronic kidney disease’ by Dr Dana Kim and Associate Professor Sradha Kotwal, which was published in the June 2024 Focus on Cardiometabolic Matters supplement of Medicine Today (pages 3 to 9), contains an error. In Box 3 on page 7, the PBS indications for dapagliflozin and empagliflozin for patients with chronic heart failure are not listed in full: the criteria should include left ventricular ejection fraction above, equal to and below 40%.

We apologise for this oversight and any confusion it may have caused. The online version and full-text PDF of this article are correct at https://medicinetoday.com.au/mt/supplements/feature-article/reducing-cardiovascular-risk-people-chronic-kidney-disease.